🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hemophagocytic lymphohistiocytosis (HLH) is a severe and life-threatening syndrome characterized by overwhelming inflammation that often leads to multiorgan failure and death if not treated promptly and appropriately. Biologically, HLH has taught us about the immune system and

🩸DLBCL Treatment&CV Management 🚨New Dx: R-CHOP or R-CEOP/R-GCVP (if CVD)➕ Radiation 🔄Relapsed>12mo: Auto SCT➡️ CAR-T(Axi-cel, Liso-cel) 🔥Refractory<12mo: CAR-T or Tafasitamab+Lenalidomide 💊Third-line: Chemoimmuno, Bispecifics, CAR-T, BTKis 🫀CV Risk? Dexrazoxane, Liposomal

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. MD Anderson Cancer Center #Leukemia ASH ashpublications.org/bloodadvances/…

If done correctly, it will be a highly impactful executive order to reduce astronomically ridiculous drug costs in the U.S.A. #CART #genetherapy #cancermed #targetedagents all unfairly prices in USA

My top 5 picks for plasma cell disorders abstracts at #ASCO25 #mmsm in no order of preference: 1) 7505: Trispecific targeting BCMA/GPRC5D, this is by the far the most disruptive advance in early development! 2) 7507: Are we curing RRMM with BCMA CART? 3) 7508: Next Gen BCMA CART

🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇

📌Cytotoxic Therapy in Metastatic Hormone-Receptor Breast Cancer: Antibody-Drug Conjugates and Chemotherapy in Focus #ASCO25 OncoAlert #OncoAlertAF

Day 1 #ASCO25 highlights: 1. Review on recent approvals 2. #BREAKWATER (update): BRAF+ mCRC 3. #CM8HW (update): MSI-H mCRC 4. #DYNAMIC: ctDNA in colon ca 5. #CAIRO6: periOP Rx in peritoneal mets #OncTwitter ASCO 1/6

1. Recent FDA Oncology approvals: - Tarlatamab: extensive stage small cell lung cancer - Epcoritamab for R/R follicular lymphoma - Dato-DXd: HR+ metastatic breast cancer - Vorasidenib Gr2 Astrocytoma/Oligodendroglioma IDH1/2 + 2/6

🚨 New Standard in 2L HER2+ Gastric Cancer? 📌 DESTINY-Gastric04 (NEJM) T-DXd vs Ramucirumab+Paclitaxel N=494, post-trastuzumab HER2+ GEJ/Gastric AC 🧬 Primary OS benefit: 🟧 14.7 mo vs 11.4 mo 🟧 HR 0.70 | p=0.004 ✅ 📉 PFS: 6.7 vs 5.6 mo 🎯 ORR: 44.3% vs 29.1% But... some

My Updated Myeloma Treatment Algorithms. #ASCO25 Bookmark! Presented at COMy. 1) Newly Diagnosed myeloma transplant ineligible.

Out now in Blood Journal, Lu et al 🙌🏽 Phase IIb Ven/Dec vs Intensive chemo (7&3) in younger adults with AML 💪🏽 1° end point: CRc after induction ➡️CRc 89% vs 79%, non inf p=0.002 💪🏽 ➡️Ven/Dec better tolerated 🙌🏽 #MedTwitter ashpublications.org/blood/article/…

#ASCO25 #Ph_pos_ALL phase 1 study presented by Dr Marlise R. Luskin MD, MSCE Asciminib+Dasatinib+Prednisone followed by blinatumomab is safe and effective in achieving deep molecular remission. #leusm

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

Day 2 #ASCO25 highlights: 1. #VERITAC2: Vepdegestrant HR+ mBC 2. #INAVO120 (update): Inavolisib HR+ mBC 3. #ASCENT04: Sacituzumab mTNBC 4. #CM577 (update): Adj Nivo GEJ/Gastric 5. #DESTINYGastric04: TDXd HER2+ GEJ/Gastric 6. #KN564 (update): Adj Pembro ccRCC ASCO 1/8

How I treat secondary acute myeloid leukemia ashpublications.org/blood/article-… #leusm #AML

Great post by David Steensma, MD highlighting the difficulties of treating neoplastic conditions. When a trial is “negative” it’s not the fault of the drug, the trial design, the investigators, or patients. Some cancers and pre cancers are just inherently hard to tackle:

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment onlinelibrary.wiley.com/doi/full/10.10…

DIC PATHOPHYSIOLOGY DIC is a paradox: clotting + bleeding. It starts with tissue factor exposure, triggering the extrinsic pathway → fibrin clots form throughout the body. But clotting factors & platelets get consumed, and fibrinolysis ramps up, leading to bleeding.

Just out: Guidelines for testing and reporting cytogenetic results in myeloma Blood Cancer Journal⁩ #OpenAccess Bookmark! Allows you to incorporate latest IMS/IMWG high risk criteria in practice. ⁦Linda B. Baughn⁩ ⁦Rahul Banerjee, MD, FACP⁩ ⁦Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽⁩ nature.com/articles/s4140…